ASCO 2024 | Anti-Müllerian hormone as a predictor of chemotherapy response in HR+/HER2- breast cancer

Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, comments on findings of the Phase III RxPONDER trial (NCT01272037), which examined the benefit of adding chemotherapy to endocrine therapy (ET) in premenopausal women with HR+/HER2- invasive breast cancer and a recurrence score (RS) ≤ 25. Baseline anti-Müllerian hormone (AMH) levels significantly predicted the benefit of chemotherapy, whereas other hormone levels did not. Patients with baseline AMH showed improved invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) with chemotherapy, highlighting AMH as a valuable marker for guiding adjuvant chemotherapy decisions. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.